Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients

Current Opinion in Hematology

Volumn 9, Issue 3, 2002, Pages 207-214

  Lyman, Gary H ^a   Kuderer, Nicole M ^a   Balducci, Lodovico ^a  

^a ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PREDNISONE; VINBLASTINE; VINCRISTINE;

AGED; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEBRILE NEUTROPENIA; GERIATRIC PATIENT; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOLID TUMOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 0036206554     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200205000-00006     Document Type: Review

References (70)

1. The Economic burden of cancer
2. Hematopoietic growth factors: Biology and clinical application
3. Filgrastim (r-metHuG-CSF): The first 10 years
4. Understanding treatment benefits and harms
5. Understanding economic analyses
6. Cancer in the elderly. Epidemiologic and clinical implications
7. Cancer care in the elderly: Cost and quality of life considerations
8. The diagnosis and treatment of cancer in the elderly: Cost effectiveness considerations
9. Suboptimal dosing in adjuvant breast cancer chemotherapy: Evidence from a nationwide survey
10. Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy
11. A multinational scoring system for identifying low-risk febrile neutropenic cancer patients
12. Hemopoietic reserve in the older cancer patient: Clinical and economic considerations
13. Patients aged > 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy
14. Hematopoietic growth factors in the older cancer patient
15. Filgrastim in patients with chemotherapy-induced febrile neutropenia: A double-blind, placebo-controlled trial
16. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors
17. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial
18. Meta-analysis of colony-stimulating factors to treat febrile neutropenia in patients receiving cancer chemotherapy
19. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
20. Recombinant granulocyte stimulating factor reduces the infectious complications of cytotoxic chemotherapy
21. Djulbegovic: Meta-analysis of granulocyte colony-stimulating factor to prevent febrile neutropenia in patients receiving cancer chemotherapy
22. Use of hematopoietic growth factors in the older cancer patient
23. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma
24. Cost-benefit of granulocyte-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy
25. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: Feasiblity and efficacy of an intensive multidrug regimen
26. Randomized trial of R-methu granulocyte Colony stimulating factors as adjunto to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma
27. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer
28. Randomized placebo-controlled phase III study of Granulocyte-macrophage Colony Stimulating factor in adult patients (> 55-70 years with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
29. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML)
30. Use of recombinant GM-CSF during and after remission-induction chemotherapy in patients aged 61 and older with acute non-lymphocytic leukemia: Final report of AML-11 a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer and the Dutch Belgian Hematology Oncology Cooperative Group
31. A placebo-controlled study of recombinant human granulocyte macrophage colony-stimulating factor administered during an induction treatment for "de novo" acute myelogenous leukemia in older patients
32. Granulocyte-macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
33. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor for elderly patients with previously untreated acute myelogenous leukemia: A Southwest Oncology Group Study
34. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia
35. A controlled study of recombinant human granulooyte clony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
36. Colony-stimulating factors may reduce complications and death in solid tumor patients with fever and neutropenia
37. A novel approach to maintain planned dose chemotherapy on time: A decision making tool to improve patient care
38. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy
39. A predictive model for neutropenia associated with cancer chemotherapy
40. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer
41. Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast carcinoma
42. Methodological issues related to health economic analysis in controlled clinical trials
43. Efficacy and cost-effectiveness in oncology: Rational allocation of cancer care resources
44. The economics of febrile neutropenia: Implications for the use of the colony-stimulating factors
45. The Epidemiology and economics of neutropenia in hospitalized cancer patients: Data from the University Health System Consortium
46. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines
47. Consensus on the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: An international viewpoint
48. Economic impact of granulopoiesis stimulating agents in the management of febrile neutropenia
49. Economic analyses of the use of the colony-stimulating factors: An update
50. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy
51. A cost analysis of hematopoietic colony-stimulating factors
52. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
53. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and leukemia group B study 9022
54. Use of hematopoietic growth factors in the treatment of acute myelogenous leukemia
55. Economic analyses of phase III Cooperative Cancer Group clinical trials: Are they feasible?
56. Cost analyses of adjunctive colony-stimulating factors for acute leukemia: An they improve clinical decision making
57. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a southwest oncology group clinical trial
58. Age dependent therapeutic and economic considerations of GM-CSF in the treatment of acute myeloblastic leukemia: Protocol GOELAM Sa3
59. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukemia
60. Economic analysis of prophylactic G-CSF after mini-beam salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma
61. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity
62. Cost-minimization analysis of prophylaxctic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma
63. Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplant
64. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: Clinical assessment and cost-effectiveness
65. The costs of peripheral blood progenitor cell reinfusion mobilization by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma
66. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplant in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit
67. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor celll rescue in high-grade non-Hodgkin's lymphoma: Clinical benefits at no extra cost
68. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplant
69. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplant from human leukocyte antigen-matched related donors
70. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: A randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim